This phase I trial aims to understand how safe, well tolerated and effective a new targeted cancer drug (BMS-986158) is in people with DIPSS-intermediate or high risk Myelofibrosis, when given alone or in combination with targeted cancer treatment (Ruxolitinib or Fedratinib).
This trial is treating patients with Dynamic International Prognostic Scoring System (DIPSS)-Intermediate or High Risk Myelofibrosis.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis
Bristol-Myers Squibb (BMS)
This trial contains two parts. Part 1 will compare the combination of BMS-986158 with either Ruxolitinib or Fedratinib and Part 2 will compared these combinations with BMS-986158 alone.
Recruiting Hospitals Read More